Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Significance: Antibodies blocking inhibitory checkpoints on T cells have been a major advance in cancer treatment. However, agonistic antibodies have had less success due to toxicity concerns. Harnessing the knowledge that agonistic antibodies require the inhibitory Fc receptor (FcR), we engineered a CD40 antibody with improved in vivo activity. Because current models fail to recapitulate important dose-limiting toxicities in patients, we developed a mouse model carrying human CD40 and FcRs. This model mirrors human toxicities and allowed for the development of an in situ vaccination approach leading to durable tumor control. These results support the rational design of immune modulating antibodies as well as stress the importance, and possible reconsiderations needed, for optimal preclinical models allowing parallel efficacy and toxicity analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 5×
“Although several aspects of the clinical trial design were suboptimal with TGN1412, the major toxicity of massive cytokine release syndrome was missed in both in vitro and nonhuman primate toxicology models.”
BackgroundInfluentialSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Self-citationDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302 · cited 2×
“MC38 tumors are moderately immunogenic in C57BL6 mice compared with more “cold” B16 melanoma tumors, possibly given the higher somatic mutational burden in MC38 versus B16 tumors (27).”
BackgroundFc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592
Cited by
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Nakamura, K., & Smyth, M. J. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0306-1 · Cited by 516
Delidakis, G., Kim, J. E., George, K., & Georgiou, G. (2022) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-082721-024500 · Cited by 87
Wang, L.-M., Yang, C., Sun, X., Tian, Y., Zhang, J., Wang, X., Zhou, L., Wang, Z., Lin, Y., Wu, T., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0999 · Cited by 2
Metadata
- Authors
- Knorr, D. A., Dahan, R., & Ravetch, J. V.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-10-08
- Volume
- 115
- Issue
- 43
- Pages
- 11048-11053
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2897324861
- Cited by
- 120
- References
- 4
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.